This article presents recommendations, based on the Grading of Recommendations, Assessment,
Development, and Evaluation method, for the clinical application of cerebrospinal fluid …

… of Alzheimer's disease (AD), which has been translated into an ongoing development of
disease-… Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). The …

… Amyloid螃 1 to 42 peptide (Aβ 1–42 ), total tau (ttau), and tau phosphorylated at the
threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline …

… genotype strongly affects the levels of cerebrospinal fluid amyloid-β 1-42 … Alzheimer's disease
CSF biomarkers in 1233 cognitively normal subjects aged 40–85 years. Alzheimer disease…

… -modifying drugs have created a need for biomarkers that reflect core elements of the
disease process. Here, we review the development of candidate cerebrospinal fluid (CSF) and …

… in disease diagnosis and prognosis, and assess disease risk … have demonstrated that
Alzheimer's disease pathology can … the most promising cerebrospinal fluid biomarkers, highlights …

… Although protein content is lower in cerebrospinal fluid (CSF) than in serum, CSF is an ideal
source for developing viable biomarkers in AD as it directly interacts with the extracellular …

… between mild cognitive impairment (MCI) and incipient Alzheimer's disease (AD). We
show that a combination of three cerebrospinal fluid biochemical markers, total-tau, phospho-tau …

… Systematic review: We searched PubMed for English language reports on diagnostic
accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD). In addition, the …

… An accurate and early diagnosis of Alzheimer’s disease (AD) is important to select optimal …
been made in the development and validation of cerebrospinal fluid (CSF) biomarkers for the …